K-numberK241790
Device nameXCELLARISPRO TWIST microneedling device
ApplicantDermaroller GmbH
Product codeQAI
Device classClass II
Decision dateMar 6, 2025
DecisionSubstantially Equivalent
Regulation878.4430
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The XCELLARISPRO TWIST is a powered microneedling device that creates microscopic punctures in facial skin using six stainless-steel needles. It is intended to improve the appearance of facial acne scars in Fitzpatrick skin types I-IV and treat wrinkles (glabellar frown lines, periorbital lines, and cheek folds) in Fitzpatrick skin types I-III in adults aged 22 or older.

Technological characteristics

The device operates at a frequency range of 50-150 Hz (recommended 100-150 Hz) with adjustable needle protrusion depth from 0-2.5 mm (recommended maximum 1.5 mm). It contains six stainless-steel needles in squared arrangement, each 2.5 mm long, mounted in a single-use sterile needling module. Key differences from predicates include a broader frequency range than the Exceed device, though with similar recommended working frequencies and identical maximum needle penetration depth of 1.5 mm.

Test standards cited

Testing performed per ISO 11737-2 and ISO 11135 (sterility), ISO 11607-1 (shelf life and package integrity), IEC 60601-1 and IEC 60601-1-2 (electrical safety and EMC), and ISO 10993-1 (biocompatibility including cytotoxicity, irritation, sensitization, and acute systemic toxicity). Non-clinical performance testing included high-speed camera measurement of needle protrusion accuracy and puncture rate in pig skin.

Substantial equivalence argument

The device shares identical product code (QAI), device classification, intended use (facial aesthetic treatment), prescription-use status, location of use (face), sterilization method (ethylene oxide), and recommended needle penetration depth (1.5 mm) with predicate devices. Although frequency range and specific design differ, non-clinical performance testing demonstrates the device performs as intended and poses no undue or additional risks. General controls and special controls (including non-clinical performance testing) establish that technical differences do not raise new safety or effectiveness questions compared to predicates.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →